首页> 外文期刊>Drug delivery and translational research >Design and optimization of film-forming gel of etoricoxib using research surface methodology
【24h】

Design and optimization of film-forming gel of etoricoxib using research surface methodology

机译:使用研究方法方法的肉食毒素成膜凝胶的设计与优化

获取原文
获取原文并翻译 | 示例
       

摘要

The present investigation is focused on the development of transdermal film-forming gel (FFG) loaded with etoricoxib employing research surface methodology (RSM). Box-Behnken surface design method was used to develop experimental run using different concentrations of etoricoxib, hydroxypropyl methylcellulose (HPMC K100M), and eudragit RL100 as independent variables, and Derringer's optimization tool was employed to optimize best possible formulation. The dependent variables considered in this study were viscosity and drug permeation at 24 h (Q24, mu g/cm(2)). Anti-inflammatory study was performed on Wistar albino rats for 8 h. Skin irritation studies and accelerated stability studies were performed for validated FFG formulations. Quadratic model was found to be best fit model (p < 0.0001) for both the responses. The influence of HPMC concentration on the viscosity was found to be highest whereas concentration of etoricoxib was maximum for Q24. The optimum composition of the FFG was observed to be 4% of etoricoxib, 1.1246% of HPMC, and 0.4% of eudragit. Above composition resulted in viscosity of 1549.5 mPa.s and maximum Q24 of 4639.11 mu g/cm(2) with desirability 0.918. The in vivo anti-inflammatory study demonstrated better sustained release effect (for 8 h) of optimized FFG compared to orally administered drug suspension. An average irritation score of 0.555 was observed on Draize scoring system. The validated FFG formulation was found to be stable for the 3 months in accelerated conditions. It can be concluded from the above investigations that the validated FFG formulation of etoricoxib is well tolerated and could provide sustained drug release for 8 h.
机译:本研究的重点是致透皮成膜凝胶(FFG)的开发,该凝胶(FFG)用etoricoxib采用研究表面方法(RSM)。 Box-Behnken表面设计方法用于使用不同浓度的肠道毒素,羟丙基甲基纤维素(HPMC K100M)和Eudragit R100作为独立变量进行实验运行,采用Derringer的优化工具来优化最佳的配方。本研究中考虑的依赖性变量在24小时时是粘度和药物渗透(Q24,mu g / cm(2))。对Wistar白化大鼠进行抗炎研究8小时。对验证的FFG制剂进行皮肤刺激性研究和加速稳定性研究。对于响应,发现二次模型是最适合的拟合模型(P <0.0001)。发现HPMC浓度对粘度的影响最高,而肉毒毒毒剂的浓度最大为Q24。将观察到FFG的最佳组合物为埃里摩毒素的4%,1.1246%的HPMC,尤金菌的0.4%。上述组合物导致粘度为1549.5MPa.s,最大Q24为4639.11μg/ cm(2),其可抵发0.918。与口服给药的药物悬浮液相比,体内抗炎研究表明优化的FFG优化的FFG持续释放效果(8小时)。在绘制评分系统上观察到平均刺激得分为0.555。发现验证的FFG制剂在加速条件下为3个月稳定。从上述研究可以得出结论,欧洲毒素的经过验证的FFG制剂耐受良好,并且可以提供8小时的持续药物释放。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号